Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Rezolute
Exelixis
Institute for Clinical and Experimental Medicine
West China Hospital
Orano Med LLC
Amgen
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Vastra Gotaland Region
Fundación de investigación HM
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Cancer Institute (NCI)
RayzeBio, Inc.
Melanoma and Skin Cancer Trials Limited
National Health Research Institutes, Taiwan
National Institutes of Health Clinical Center (CC)
ITM Solucin GmbH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Turning Point Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Ipsen
RayzeBio, Inc.
Boston Scientific Corporation
Melanoma and Skin Cancer Trials Limited
National Institutes of Health Clinical Center (CC)
Centre Hospitalier Universitaire Dijon
University Health Network, Toronto
Methodist Health System
Novartis
M.D. Anderson Cancer Center
Crinetics Pharmaceuticals Inc.
University of Wisconsin, Madison